Exploring the role of serum adiponectin and its holigomerization in fibrotic interstitial lung diseases: results from a cross-sectional study
Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progressi...
Saved in:
Published in | BMC pulmonary medicine Vol. 25; no. 1; pp. 263 - 9 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
26.05.2025
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1471-2466 1471-2466 |
DOI | 10.1186/s12890-025-03706-w |
Cover
Abstract | Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients – divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8–15.4] versus 19.3 [17.3–20.8]
p
< 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups (
p
= 0.619). Adiponectin levels were not associated with progression of f-ILDs (
p
= 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs – but not in other subgroups – adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs. |
---|---|
AbstractList | Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients - divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8-15.4] versus 19.3 [17.3-20.8] p < 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups (p = 0.619). Adiponectin levels were not associated with progression of f-ILDs (p = 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs - but not in other subgroups - adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs. Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients – divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8–15.4] versus 19.3 [17.3–20.8] p < 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups ( p = 0.619). Adiponectin levels were not associated with progression of f-ILDs ( p = 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs – but not in other subgroups – adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs. Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients - divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8-15.4] versus 19.3 [17.3-20.8] p < 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups (p = 0.619). Adiponectin levels were not associated with progression of f-ILDs (p = 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs - but not in other subgroups - adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs. Keywords: Interstitial lung diseases, Idiopathic pulmonary fibrosis, Connective tissue diseases, Adypokines, Adiponectin Abstract Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients – divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8–15.4] versus 19.3 [17.3–20.8] p < 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups (p = 0.619). Adiponectin levels were not associated with progression of f-ILDs (p = 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs – but not in other subgroups – adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs. Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients - divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8-15.4] versus 19.3 [17.3-20.8] p < 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups (p = 0.619). Adiponectin levels were not associated with progression of f-ILDs (p = 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs - but not in other subgroups - adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs.Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients - divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8-15.4] versus 19.3 [17.3-20.8] p < 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups (p = 0.619). Adiponectin levels were not associated with progression of f-ILDs (p = 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs - but not in other subgroups - adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs. |
ArticleNumber | 263 |
Audience | Academic |
Author | Perrotta, Fabio Picone, Carmine Mallardo, Marta Pagliaro, Raffaella D’Agnano, Vito Daniele, Aurora D’Errico, Adolfo Gallipoli Nigro, Ersilia Bianco, Andrea |
Author_xml | – sequence: 1 givenname: Ersilia surname: Nigro fullname: Nigro, Ersilia organization: Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli studi della Campania Luigi Vanvitelli, CEINGE Advanced Biotechnology “Franco Salvatore” scarl – sequence: 2 givenname: Vito surname: D’Agnano fullname: D’Agnano, Vito organization: Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”, U.O.C. Pneumology L. Vanvitelli, A.O. dei Colli, Monaldi Hospital – sequence: 3 givenname: Raffaella surname: Pagliaro fullname: Pagliaro, Raffaella organization: Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”, U.O.C. Pneumology L. Vanvitelli, A.O. dei Colli, Monaldi Hospital – sequence: 4 givenname: Marta surname: Mallardo fullname: Mallardo, Marta organization: Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli studi della Campania Luigi Vanvitelli, CEINGE Advanced Biotechnology “Franco Salvatore” scarl – sequence: 5 givenname: Andrea surname: Bianco fullname: Bianco, Andrea organization: Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”, U.O.C. Pneumology L. Vanvitelli, A.O. dei Colli, Monaldi Hospital – sequence: 6 givenname: Carmine surname: Picone fullname: Picone, Carmine organization: Division of Radiology, Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli, Department of Medicine and Health Science, Vincenzo Tiberio University of Molise – sequence: 7 givenname: Adolfo Gallipoli surname: D’Errico fullname: D’Errico, Adolfo Gallipoli organization: Lega Italiana per la Lotta contro i Tumori – sequence: 8 givenname: Aurora surname: Daniele fullname: Daniele, Aurora organization: CEINGE Advanced Biotechnology “Franco Salvatore” scarl, Department of Molecular Medicine and Medical Biotechnology (DMMBM), University of Naples ’Federico II’ – sequence: 9 givenname: Fabio surname: Perrotta fullname: Perrotta, Fabio email: fabio.perrotta@unicampania.it organization: Department of Translational Medical Sciences, University of Campania “L. Vanvitelli”, U.O.C. Pneumology L. Vanvitelli, A.O. dei Colli, Monaldi Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40420027$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkk1v1DAQhiNURD_gD3BAlrhwSfFH7GS5oKoqUKkSFzhbjjPedeXEwXa6LP-B_4yzu7RdhBDywZb9zuN5Z-a0OBr8AEXxkuBzQhrxNhLaLHCJKS8xq7Eo10-KE1LVpKSVEEePzsfFaYy3GJO64exZcVzhimJM65Pi59X30flghyVKK0DBO0DeoAhh6pHq7Ji_1MkOSA0dsimilXd26XsI9odK1g8ovxnbBp-szucEISabrHLITRna2QgqQnyHAsTJZYAJPpORDj7GMs5wP2R1TFO3eV48NcpFeLHfz4qvH66-XH4qbz5_vL68uCk1FySVxhAheC2I4BWmwEiHFWCx0FQAxcLwRcMM4Ywo1XJuuto02qi240wBhVqws-J6x-28upVjsL0KG-mVldsLH5ZShWzIgWSGE2GEWiw4rypMlK7bpmurVugqZ4Mzi-1Y0zCqzVo5dw8kWM6NkrtGydwouW2UXOeo97uocWp76DQMKSh3kMrhy2BXcunvJKEEc7ZgmfBmTwj-2wQxyd5GDc6pAfwUJaNkXjnnLH39h_TWTyFXfasS2QVv2INqqbJvOxifP9YzVF40FRFVLfisOv-LKq8OeqvztBib7w8CXj12em_x9wxmAd0JtiMRwPxf_fZVj-M8vBAeLP0j6hcGzgAz |
Cites_doi | 10.1177/1479972316674425 10.1164/rccm.201308-1483ST 10.1016/j.resp.2023.104109 10.1183/13993003.01112-2022 10.1007/s40139-015-0094-y 10.1164/ajrccm.166.1.at1102 10.1155/2015/124624 10.1152/ajpendo.00110.2003 10.1016/S0140-6736(21)01961-9 10.1016/j.chest.2019.10.011 10.1136/thoraxjnl-2012-201581 10.3390/ijms20040912 10.1016/j.lfs.2020.117995 10.3390/life13020444 10.3389/fimmu.2023.1244586 10.1152/ajplung.00037.2024 10.5152/eurjrheum.2020.19107 10.1186/s12890-023-02783-z 10.3109/s10165-012-0660-7 10.1007/s11154-013-9271-7 10.1016/j.imbio.2020.151997 10.1164/rccm.202405-0977OC 10.7326/0003-4819-156-10-201205150-00004 10.3390/biom10060926 10.1164/rccm.202202-0399ST 10.1183/23120541.00124-2023 10.1164/rccm.201807-1255ST 10.1038/oby.2008.275 |
ContentType | Journal Article |
Copyright | The Author(s) 2025 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY DOA |
DOI | 10.1186/s12890-025-03706-w |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database (ProQuest) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 6 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2466 |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_3f516f6a99554401ac7b8db4b6c4c560 10.1186/s12890-025-03706-w PMC12105393 A841647653 40420027 10_1186_s12890_025_03706_w |
Genre | Journal Article Observational Study |
GeographicLocations | Italy |
GeographicLocations_xml | – name: Italy |
GrantInformation_xml | – fundername: Lega Italiana per la Lotta contro i Tumori |
GroupedDBID | --- 0R~ 23N 2WC 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX CITATION ALIPV CGR CUY CVF ECM EIF NPM PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. M48 PKEHL PQEST PQUKI PRINS 7X8 5PM 2VQ 4.4 ADTOC AHSBF C1A EJD H13 IPNFZ RIG UNPAY |
ID | FETCH-LOGICAL-c561t-ff166576165402e31d0ae069c26e206f5983f1531aab55fd7f8cfabd53ae2e763 |
IEDL.DBID | 7X7 |
ISSN | 1471-2466 |
IngestDate | Wed Aug 27 01:27:34 EDT 2025 Wed Oct 01 16:15:25 EDT 2025 Tue Sep 30 17:03:10 EDT 2025 Fri Sep 05 15:59:48 EDT 2025 Fri Jul 25 09:29:15 EDT 2025 Tue Jun 17 21:56:04 EDT 2025 Tue Jun 10 21:07:59 EDT 2025 Thu Jun 26 01:52:16 EDT 2025 Wed Oct 01 06:02:35 EDT 2025 Sat Sep 06 07:21:53 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Adypokines Interstitial lung diseases Connective tissue diseases Idiopathic pulmonary fibrosis Adiponectin |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. cc-by-nc-nd |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c561t-ff166576165402e31d0ae069c26e206f5983f1531aab55fd7f8cfabd53ae2e763 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://www.proquest.com/docview/3216560583?pq-origsite=%requestingapplication% |
PMID | 40420027 |
PQID | 3216560583 |
PQPubID | 44785 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_3f516f6a99554401ac7b8db4b6c4c560 unpaywall_primary_10_1186_s12890_025_03706_w pubmedcentral_primary_oai_pubmedcentral_nih_gov_12105393 proquest_miscellaneous_3212121440 proquest_journals_3216560583 gale_infotracmisc_A841647653 gale_infotracacademiconefile_A841647653 pubmed_primary_40420027 crossref_primary_10_1186_s12890_025_03706_w springer_journals_10_1186_s12890_025_03706_w |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-05-26 |
PublicationDateYYYYMMDD | 2025-05-26 |
PublicationDate_xml | – month: 05 year: 2025 text: 2025-05-26 day: 26 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | BMC pulmonary medicine |
PublicationTitleAbbrev | BMC Pulm Med |
PublicationTitleAlternate | BMC Pulm Med |
PublicationYear | 2025 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | 3706_CR23 3706_CR25 3706_CR24 M d’Alessandro (3706_CR27) 2020; 225 3706_CR21 B Ley (3706_CR14) 2012; 156 3706_CR20 M Zielinski (3706_CR9) 2023; 315 M Wapenaar (3706_CR16) 2017; 14 G Raghu (3706_CR11) 2018; 198 A Daniele (3706_CR18) 2008; 16 3706_CR15 P-H Park (3706_CR3) 2015; 3 3706_CR12 AS Patel (3706_CR17) 2012; 67 3706_CR2 3706_CR10 J Nemeth (3706_CR28) 2024; 327 3706_CR4 3706_CR6 3706_CR7 WD Travis (3706_CR1) 2013; 188 3706_CR8 KW Frommer (3706_CR26) 2020; 7 G Raghu (3706_CR19) 2022; 205 M d’Alessandro (3706_CR22) 2020; 256 ATS statement (3706_CR13) 2002; 166 JM Bruun (3706_CR5) 2003; 285 |
References_xml | – volume: 14 start-page: 140 year: 2017 ident: 3706_CR16 publication-title: Chron Respir Dis doi: 10.1177/1479972316674425 – volume: 188 start-page: 733 year: 2013 ident: 3706_CR1 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201308-1483ST – volume: 315 start-page: 104109 year: 2023 ident: 3706_CR9 publication-title: Respir Physiol Neurobiol doi: 10.1016/j.resp.2023.104109 – ident: 3706_CR12 doi: 10.1183/13993003.01112-2022 – volume: 3 start-page: 243 year: 2015 ident: 3706_CR3 publication-title: Curr Pathobiol Rep doi: 10.1007/s40139-015-0094-y – volume: 166 start-page: 111 year: 2002 ident: 3706_CR13 publication-title: Am J Respir Crit Care Med doi: 10.1164/ajrccm.166.1.at1102 – ident: 3706_CR25 doi: 10.1155/2015/124624 – volume: 285 start-page: E527 year: 2003 ident: 3706_CR5 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00110.2003 – ident: 3706_CR24 doi: 10.1016/S0140-6736(21)01961-9 – ident: 3706_CR20 doi: 10.1016/j.chest.2019.10.011 – volume: 67 start-page: 804 year: 2012 ident: 3706_CR17 publication-title: Thorax doi: 10.1136/thoraxjnl-2012-201581 – ident: 3706_CR2 doi: 10.3390/ijms20040912 – volume: 256 start-page: 117995 year: 2020 ident: 3706_CR22 publication-title: Life Sci doi: 10.1016/j.lfs.2020.117995 – ident: 3706_CR8 doi: 10.3390/life13020444 – ident: 3706_CR6 doi: 10.3389/fimmu.2023.1244586 – volume: 327 start-page: L487 year: 2024 ident: 3706_CR28 publication-title: Am J Physiol Lung Cell Mol Physiol doi: 10.1152/ajplung.00037.2024 – volume: 7 start-page: S165 year: 2020 ident: 3706_CR26 publication-title: Eur J Rheumatol doi: 10.5152/eurjrheum.2020.19107 – ident: 3706_CR23 doi: 10.1186/s12890-023-02783-z – ident: 3706_CR21 doi: 10.3109/s10165-012-0660-7 – ident: 3706_CR4 doi: 10.1007/s11154-013-9271-7 – volume: 225 start-page: 151997 year: 2020 ident: 3706_CR27 publication-title: Immunobiology doi: 10.1016/j.imbio.2020.151997 – ident: 3706_CR10 doi: 10.1164/rccm.202405-0977OC – volume: 156 start-page: 684 year: 2012 ident: 3706_CR14 publication-title: Ann Intern Med doi: 10.7326/0003-4819-156-10-201205150-00004 – ident: 3706_CR7 doi: 10.3390/biom10060926 – volume: 205 start-page: e18 year: 2022 ident: 3706_CR19 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.202202-0399ST – ident: 3706_CR15 doi: 10.1183/23120541.00124-2023 – volume: 198 start-page: e44 year: 2018 ident: 3706_CR11 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201807-1255ST – volume: 16 start-page: 1869 year: 2008 ident: 3706_CR18 publication-title: Obes (Silver Spring) doi: 10.1038/oby.2008.275 |
SSID | ssj0017853 |
Score | 2.3842943 |
Snippet | Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might... Abstract Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients... |
SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 263 |
SubjectTerms | Adipocytes Adiponectin Adiponectin - blood Adypokines Aged Analysis Autoimmune diseases Biological markers Biomarkers Biomarkers - blood Body fat Care and treatment Case-Control Studies Chronic obstructive pulmonary disease Connective tissue diseases Consent Critical Care Medicine Cross-Sectional Studies Development and progression Diagnosis Disease Progression Enzyme-linked immunosorbent assay Female Gender Humans Idiopathic pulmonary fibrosis Idiopathic Pulmonary Fibrosis - blood Idiopathic Pulmonary Fibrosis - physiopathology Intensive Internal Medicine Interstitial lung diseases Lung - physiopathology Lung diseases Lung diseases, Interstitial Lung Diseases, Interstitial - blood Lung Diseases, Interstitial - physiopathology Male Medicine Medicine & Public Health Middle Aged Molecular weight Performance evaluation Pneumology/Respiratory System Population Prospective Studies Pulmonary fibrosis Respiratory function Respiratory Function Tests Sarcoidosis Skin cancer |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kDz4O4tvoKi0IHtywSTrdSbyt4rII68mFvTWVfujAmAybCYM_wv9sVefhREE9yBwCU52ku-vrqq7Uoxl7qSSaa64QscBrnAsPuKSkizMDtpC18j5kyJ1_VGcX-YdLebl31BfFhA3lgYeJOxZepsorqCpUfGgMgCnq0tZ5rUxuUF2T9EU1NhlTo_-gQC00pciU6rhLyZ8W09GtiSjQht4t1FCo1v-7TN5TSr8GTM5e01vsRt9s4NsO1us9xXR6h90ed5T8ZBjJXXbNNffY9fPRZ36ffZ_D7Dhu9jiFE_LWc4Re_5WDXW3ahoRew6GxfLXtOMrD1eeWPDlDiiZHmkerusUXcCovcUXxBYhbvkZJwUcXT_eGo-Xer_EBlLLCgYeRx12I9aIehkq2D9jF6ftP787i8RCGGGc33cbep-ScUZT1lGROpDYBl6jKZMplifKyKoVHsZkC1FJ6W_jSeKitFOAQBEo8ZAcNDuQx42g7UVvwqcVdGFRgXQneZsIovDPxEXs98URvhlobOtgopdIDBzVyUAcO6l3E3hLb5pZUJzv8gejRI3r039ATsVfEdE2rGTlrYExKwA5TXSx9Ql7ZvFBSROxw0RJXoVmSJ9joUQp0WmShtpEskfxiJtOdFNnWuLYPbeiHnYvYowFl85BylKj03SBi5QJ_izEvKc3qS6gRTnXhpKjwxUcTVH_260-TejTD-R948OR_8OApu5mFlUnhlofsYHvVu2e409vWz8Oi_gH-yFDf priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Li9RAEG50BR8H8W10lRYED24wSac7ibd1cFmE9eTC3ppKP3RgTIbNhMEf4X-2qpOJExVR5jAw3Z10zVdVXZV6hLGXSqK75goRC_yOc-EBRUq6ODNgC1kr70OF3NlHdXqef7iQF2ObHKqF2Y_fp6V606UUCYvppauJKND73V5l1yQqXkrfW6jFFDEo8NzZFcX8cd3s4An9-X_XwnvH0K8pklOc9Ba70Tdr-LaF1WrvKDq5w26PNiQ_HkC_y6645h67fjZGye-z71NiHUfzjlMCIW89R2brv3Kwy3XbkJprODSWLzcdRw24_NxS7GYoyuQ45tGPbvEGnBpKXFJGAXIqX6Fu4GNQp3vL0VfvV3gBKlLhwAPlcReyu2iHoXftA3Z-8v7T4jQeX7sQGzSmNrH3KYVjFNU5JZkTqU3AJaoymXJZorysSuFRUaYAtZTeFr40HmorBTiEXYmH7KBBQh4zjt4SzQWfWrS7oALrSvA2E0bhysRH7PUOE70eumvo4JWUSg8IakRQBwT1NmLvCLZpJnXGDj8gw-hR0LTwMlVeQVWhoYTOI5iiLm2d18rkSF8SsVcEuib5RWQNjGUIuGHqhKWPKQ6bF0qKiB3OZqLcmfnwjm30KPedFlnoZiRLHH4xDdNKymVrXNuHOfTBzUXs0cBlE0k56lB6UhCxcsZ_M5rnI83yS-gKTp3gpKjwxkc7Vv25r7_9qUcTO_8DBk_-7-pP2c0syCClUh6yg81l756hFbepnwfx_QGZnkIE priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1di9QwMOge-PHg56nVUyIIPnjda5smbX1bxeMQ7vDBhfMppG1yLnbbst2y6H_wPzuTduv2FFGQfShsJm1mOjOZ6XyEkBeCg7umI-YyuLohMwpEims3yFQe8VQYYyvkTs_EyTx8f87P--OAsBYmXWZ1WyxhJ5ju1p8XXXkDHp-gV0d1bjppj8VR42OozMVTWT0WgXu8uUr2BEabJmRvfvZh9snWF0W-G4RCbMtmfjtxtDXZDv6_6umdjepyEuUQSb1Jrrdlrb5uVFHsbFbHt0mxRbPLUfkybdfpNPt2qQPkf6LDHXKrN2rprOPCu-SKLu-Ra6d92P4--T5k-lGwNylmNNLKUOD-dklVvqirEvVuSVWZ08W6oaCSFxcVBpO6KlEKYwYc-woeQLHDxQpTHEB0aAHKivZRpuY1XemmLeAGWDVDFbWEdhubboYrtM1098n8-N3Htydufw6Em4F1t3aN8TE-JLDwygs083NPaU8kWSB04AnDk5gZ0Ny-UinnJo9MnBmV5pwpDXwo2AMyKQGRR4SC-4awyvg5GIIqUbmOlckDlgmY6RmHvNqygKy7dh_SukmxkB2FJVBYWgrLjUPeIJcMkNiq2_5RrS5kL_mSGe4LI1SSgOUG3qzKojTO0zAVWQj4eQ55iTwmUaHAG85UXxcBC8bWXHKGgeEwEpw55GAECYogGw9vuVT2iqiRLLDtlXgMw8-HYZyJyXWlrloLgz9YnEMedkw9oBSCUsdPFw6JR-w-wnk8Ui4-2zbl2JqOswQefLiVjJ_r-hNRDwfp-Yt38PjfwJ-QG4GVEcztPCCT9arVT8GsXKfPenXxA4ZqdOs priority: 102 providerName: Unpaywall |
Title | Exploring the role of serum adiponectin and its holigomerization in fibrotic interstitial lung diseases: results from a cross-sectional study |
URI | https://link.springer.com/article/10.1186/s12890-025-03706-w https://www.ncbi.nlm.nih.gov/pubmed/40420027 https://www.proquest.com/docview/3216560583 https://www.proquest.com/docview/3212121440 https://pubmed.ncbi.nlm.nih.gov/PMC12105393 https://bmcpulmmed.biomedcentral.com/counter/pdf/10.1186/s12890-025-03706-w https://doaj.org/article/3f516f6a99554401ac7b8db4b6c4c560 |
UnpaywallVersion | publishedVersion |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: KQ8 dateStart: 20010901 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: DIK dateStart: 20010101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: RPM dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: AAJSJ dateStart: 20011201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1471-2466 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017853 issn: 1471-2466 databaseCode: C6C dateStart: 20011201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1ra9swUGwt7PFh7NXNWxc0GOzDampblmzvy0hCSxk0lLJAti9CtqwukNlZHBP2I_afdyc_Wm9QRiAhOdnW5R660z1EyDvBwV3LI-Yy-HRDZhSIFM_dIFM64qkwxlbInc_E2Tz8vOCLdsOtatMqO51oFbUuM9wjP2aB7RPDY_Zp_dPFU6MwutoeoXGX7PtgqiBXR4ve4cKD51lXKBOL48rHqJqLB7h6LAJPejdYjGzP_n81842l6e-0yT52-pDcr4u1-rVTq9WN5en0MXnU2pV03DDCE3InL56Se-dt5PwZ-d0n21Ew-SgmFdLSUGDA-gdVerkuC1R9BVWFpsttRUErLq9KjOc0hZoUYAZ86xIeQLHJxAazDIB76Qr0BW0DPdVHCv57vYIbYOEKVdRi7lY24wtnaPvZPifz05Mv0zO3PYrBzcDA2rrG-BiiEVj75AU587Wnck8kWSDywBOGJzEzoDx9pVLOjY5MnBmVas5UDqwg2AHZKwCRl4SCB4VjlfE12GIqUTqPldEBywRc6RmHfOhoItdNxw1pPZVYyIaCEigoLQXlziETJFs_Ertl2x_KzZVshU8yw31hhEoSMJ7AoVRZlMY6DVORhYCf55D3SHSJMg2UzVRbmgATxu5Ycoyx2TASnDnkcDASZDEbgju2ka0uqOQ15zrkbQ_GKzG_rcjL2o7BF0zOIS8aLutRCkGv4u6BQ-IB_w1wHkKK5XfbKRy7w3GWwIOPOla9ntdtf-pRz87_QYNXt2P9mjwIrMxhOuUh2dtu6vwNWHLbdGTFdUT2Jyezi0v4NhXTkd0VgffLyTeAzGcX469_AJb_Tss |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CpFonBAvAkUMBKIA42axLGTICFUHtWWdntqpd6ME9tlpSVZNrta9SP4Fb6RGefRBqSKS5VDpNhJPJmHZzIvQl4JDuaaSZjP4OzHzCpgKW78qFA64bmw1mXIjQ_F6Dj-esJP1sjvLhcGwyo7megEta4K_Ee-zSJXJ4an7MPsp49do9C72rXQaMhi35ytwGSr3-99Bvy-jqLdL0efRn7bVcAvQFdY-NaG6G0QmMYTRIaFOlAmEFkRCRMFwvIsZRbkQKhUzrnViU0Lq3LNmTIAlWDw3GvkesyCGGv1Jye9gYeN7lmXmJOK7TpEL56PDWMDloDlvhpsfq5HwL87wYWt8O8wzd5Xe4tsLMuZOlup6fTCdrh7h9xu9Vi60xDeXbJmynvkxrj11N8nv_rgPgoqJsUgRlpZCgS__EGVnsyqEkVtSVWp6WRRU5DCk9MK_UdNYiiFMQu2fAUvoFjUYo5RDcAtdAryibaOpfodnZt6OYUHYKIMVdRB7tcuwgxX6OrnPiDHV4Kkh2S9BEAeEwoWG85VNtSg-6lMaZMqqyNWCLgzsB552-FEzpoKH9JZRqmQDQYlYFA6DMqVRz4i2vqZWJ3bXajmp7JldsksD4UVKstAWQMDVhVJnuo8zkURA3yBR94g0iXKEMBsodpUCFgwVuOSO-gLjhPBmUc2BzOB94vhcEc2spU9tTznFI-87IfxToynK021dHPwgMV55FFDZT1IMchx_FvhkXRAfwOYhyPl5LurTI7V6DjL4MVbHamer-uyj7rVk_N_4ODJ5VC_IBujo_GBPNg73H9KbkaO_zCUc5OsL-ZL8wy0yEX-3LEuJd-uWlb8AUK4hUI |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgkwY8IL4XGGAkJB5YtCSOnYS38lGNwiYkmLQ3y4ntUalLqiZRxR_B_8ydk4YGEAL1oVJtJ77eh-9yd78Q8lxwCNdMwnwG337MrAKV4saPCqUTngtrXYfcyak4Potn5_x8q4vfVbtvUpJdTwOiNJXN0VLbTsVTcVSHmB_z8VWsAUsgJl5fJbspzwSEX7uTyezzbMgkJHAebZpl_rhydCA53P7frfPW8fRr6eSQP71BrrXlUn1bq8Vi64ia3iI3e9-STjphuE2umPIO2Tvps-d3yfeh4I6C20exsJBWloIQtpdU6fmyKtH8lVSVms6bmoJlnF9UmNPpmjUpjFmIryu4AUWgiRVWGoAE0wXYDNone-pXFGL4dgEXwOYVqqij3K9d1Rfu0GHa3iNn03df3hz7_esY_AKcrMa3NsQ0jcD-pyAyLNSBMoHIikiYKBCWZymzYEBDpXLOrU5sWliVa86UAXEQ7D7ZKYGQfUIhisK5yoYa_DGVKW1SZXXECgErA-uRlxueyGWHuiFdtJIK2XFQAgel46Bce-Q1sm2YiYjZ7odqdSF7BZTM8lBYobIMHCgIKlWR5KnO41wUMdAXeOQFMl2iXgNnC9W3J8CGESFLTjA_GyeCM48cjGaCPhbj4Y3YyN4e1JJFDuWIpzD8bBjGlVjjVpqqdXPwA5vzyINOygaSYrCt-ATBI-lI_kY0j0fK-VeHFo4IcZxlcOPDjaj-3Nff_tTDQZz_gQcP_-_qT8nep7dT-fH96YdH5Hrk1BGrLQ_ITrNqzWNw9Jr8Sa_LPwCOME6v |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1di9QwMOge-PHg56nVUyIIPnjda5smbX1bxeMQ7vDBhfMppG1yLnbbst2y6H_wPzuTduv2FFGQfShsJm1mOjOZ6XyEkBeCg7umI-YyuLohMwpEims3yFQe8VQYYyvkTs_EyTx8f87P--OAsBYmXWZ1WyxhJ5ju1p8XXXkDHp-gV0d1bjppj8VR42OozMVTWT0WgXu8uUr2BEabJmRvfvZh9snWF0W-G4RCbMtmfjtxtDXZDv6_6umdjepyEuUQSb1Jrrdlrb5uVFHsbFbHt0mxRbPLUfkybdfpNPt2qQPkf6LDHXKrN2rprOPCu-SKLu-Ra6d92P4--T5k-lGwNylmNNLKUOD-dklVvqirEvVuSVWZ08W6oaCSFxcVBpO6KlEKYwYc-woeQLHDxQpTHEB0aAHKivZRpuY1XemmLeAGWDVDFbWEdhubboYrtM1098n8-N3Htydufw6Em4F1t3aN8TE-JLDwygs083NPaU8kWSB04AnDk5gZ0Ny-UinnJo9MnBmV5pwpDXwo2AMyKQGRR4SC-4awyvg5GIIqUbmOlckDlgmY6RmHvNqygKy7dh_SukmxkB2FJVBYWgrLjUPeIJcMkNiq2_5RrS5kL_mSGe4LI1SSgOUG3qzKojTO0zAVWQj4eQ55iTwmUaHAG85UXxcBC8bWXHKGgeEwEpw55GAECYogGw9vuVT2iqiRLLDtlXgMw8-HYZyJyXWlrloLgz9YnEMedkw9oBSCUsdPFw6JR-w-wnk8Ui4-2zbl2JqOswQefLiVjJ_r-hNRDwfp-Yt38PjfwJ-QG4GVEcztPCCT9arVT8GsXKfPenXxA4ZqdOs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploring+the+role+of+serum+adiponectin+and+its+holigomerization+in+fibrotic+interstitial+lung+diseases%3A+results+from+a+cross-sectional+study&rft.jtitle=BMC+pulmonary+medicine&rft.au=Nigro%2C+Ersilia&rft.au=D%E2%80%99Agnano%2C+Vito&rft.au=Pagliaro%2C+Raffaella&rft.au=Mallardo%2C+Marta&rft.date=2025-05-26&rft.pub=BioMed+Central&rft.eissn=1471-2466&rft.volume=25&rft_id=info:doi/10.1186%2Fs12890-025-03706-w&rft.externalDocID=PMC12105393 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2466&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2466&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2466&client=summon |